J Korean Neurol Assoc.  2023 Aug;41(3):204-209. 10.17340/jkna.2023.3.5.

New-onset Refractory Status Epilepticus after BNT162b2 mRNA COVID-19 Vaccination

• Kim HK
• Jang YJ
• Seo T
• Roh YJ
• Shin JW

• KMID: 2544800
• DOI: http://doi.org/10.17340/jkna.2023.3.5

Abstract

Increasing importance of vaccination during coronavirus disease 2019 (COVID-19) pandemic, several vaccines were developed. Messenger RNA (mRNA) vaccines including BNT162b2 (Pfizer, New York, NY, USA; BioNTech, Mainz, Germany), mRNA-1273 (Moderna, Cambridge, MA, USA) have been disclosed side effects such as thrombocytopenia, myocarditis and headache in general. In addition, adverse effects due to autoimmune responses induced by spike glycoproteins of mRNA vaccines are rarely reported such as the Guillain-Barre syndrome, autoimmune encephalitis and so on. Herein, we report a rare case of encephalitis with new-onset refractory status epilepticus after BNT162b2 mRNA COVID-19 vaccination improved with immune therapy.

Keyword

BNT162 vaccine; Status epilepticus; Immunotherapy